Biogen
New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016
June 8, 2016Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5
Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …
Biogen MS drug misses primary endpoint in Phase II trial
June 8, 2016Research and Development Biogen, MS, multiple sclerosis, opicinumab
Biogen has reported top-line results in the Phase II trial evaluating opicinumab (anti-Lingo-1) in relapsing forms of multiple sclerosis, with …
Biogen Alzheimer’s treatment accepted into EMA’s PRIME scheme
June 2, 2016Research and Development, Sales and Marketing Alzheimer's, Biogen, EMA, PRIME, accelerated approval
Biogen (NASDAQ: BIIB) has announced that the European Medicines Agency (EMA) has accepted its investigational treatment for Alzheimer’s disease, aducanumab, …
Biogen says European regulatory committee adopts positive view for Tysabri
June 1, 2016Medical Communications, Research and Development, Sales and Marketing Biogen, CHMP, EMA, Tysabri, multiple sclerosis
Biogen (Nasdaq: BIIB) said the European regulatory committee has backed the approval of a variation to the marketing authorization for its …
EU green-lights Samsung Bioepis, Biogen’s Remicade biosimilar Flixabi
May 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Samsung Bioepis, biosimilar, drug trial, regulation, research
Samsung Bioepis and partner Biogen (Nasdaq: BIIB) said the European Commission has approved Flixabi, a biosimilar version of Johnson & …
Biogen signs $2 billion partnership deal with UPenn for gene therapies
May 17, 2016Research and Development, Sales and Marketing Biogen, collaboration, deal, gene therapy, research
Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to …
Sobi, Biogen’s haemophilia B therapy gets European approval
May 13, 2016Medical Communications, Research and Development, Sales and Marketing Biogen, haemophilia B, orphan designation, regulation, sobi
Sobi (STO: SOBI) and Biogen (Nasdaq: BIIB) on Friday said the European Commission has approved their drug to treat haemophilia B. The …
Biogen to spin off its haemophilia business
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Business, alprolix, eloctate, haemophilia, hemophilia, spin off, spin-off
Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …
EMA recommends Biogen’s MS treatment Zinbryta
May 3, 2016Research and Development, Sales and Marketing Biogen, CHMP, EMA, daclizumab, zinbryta
The Committee for Medicinal Products for Human Use (CMHP) has recommended the granting of a marketing authorisation for Zinbryta (daclizumab) …
New head of R&D at Biogen
April 27, 2016Research and Development Biogen, Pfizer, R&D, erhlers, michael, michael erhlers, research and development
Biogen (NASDAQ: BIIB) has announced the appointment of Dr Michael Ehlers as executive vice president, research and development. His role …
Biogen Q1 profits rise boosted by Tecfidera sales
April 22, 2016Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera
Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …
Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis
Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …
Sobi and Biogen’s haemophilia A treatment EU-approved
November 27, 2015Sales and Marketing Biogen, elocta, haemophilia a, sobi
Elocta, the haemophilia A treatment developed by the Swedish Orphan Biovitrum (Sobi) and Biogen, has received European Commission approval as …
Executive vice president Tony Kingsley leaves Biogen
October 22, 2015Biogen, John Cox, Tony Kingsley
Biogen has begun the search for a replacement for Tony Kingsley, former executive vice president of global commercial operations.Kingsley will …
Revenues up at Biogen – but job losses planned
October 22, 2015Biogen, financial results, job losses, redundancies
Despite lower than predicted sales of its top-selling products, Biogen has achieved $2.8 billion in revenues in the third quarter …
Latest content
